Mode
Text Size
Log in / Sign up

Frontotemporal dementia

Part of Dementia

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Frontotemporal dementia

11 trials tracked for Frontotemporal dementia: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 72 citations.

11Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 2 Phase 1 1 Other / NA 7
  1. Phase 3 The Healthy Patterns Sleep Study Completed · 72 cited
  2. Phase 2 Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls. Completed
  3. Phase 2 A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2) Completed
  4. Phase 1 Flortaucipir PET Imaging in Subjects With FTD Completed
  5. N/A A Relational Research Recruitment and Engagement Intervention for Cognitive Aging Research Completed
  6. N/A Efficacy of Web-Based Social-Cognitive Interventions in Right Hemisphere Stroke and Frontotemporal Dementia Completed
Show 5 more trials
  1. N/A In-Home Technology for Dementia Caregivers Completed
  2. N/A Efficacy Study of Kinto Care Coaching for Dementia Family Caregivers Completed
  3. N/A Support Via Technology: Living and Learning With Advancing FTD Completed
  4. N/A Rural Dementia Caregiver Project Completed
  5. N/A Care of Persons With Dementia in Their Environments (COPE) in Programs of All-Inclusive Care of the Elderly (PACE) Completed

Showing the 11 most-cited and recently-updated of 11 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Frontotemporal dementia: what the trials found

In a large Phase 3 trial (N=421), an attention-control condition was evaluated for frontotemporal dementia, but no specific outcome results were reported 1.

A Phase 2 trial (N=33) found that AL001 increased CSF progranulin (PGRN) levels by 59.73% to 198.16% and plasma PGRN by 151.32% to 188.12% over time 2.

The Building Better Caregivers Workshop (N=418) showed mixed results: depression scores (PHQ-8) were 5.7 vs 7.1, stress scores 6.0 vs 5.9, and caregiver self-efficacy 5.4 vs 5.1, with no p-values reported 6.

Recent results — preliminary, needs further review

  • AL001 (Phase 2, N=33) demonstrated substantial increases in CSF and plasma PGRN, suggesting target engagement 2.
  • STELLA-FTD (Phase N/A, N=16) is being investigated as a recent intervention 5.
  • Building Better Caregivers Workshop (N=418) showed mixed effects on caregiver outcomes 6.

For the clinician treating this condition

  • AL001 shows promise in increasing progranulin levels, a key biomarker in FTD, but requires further validation.
  • Caregiver interventions like Building Better Caregivers Workshop have mixed evidence; consider individual patient needs.
  • Most trials are early-phase or unconfirmed; no established disease-modifying therapies are available.

AI synthesis of 4 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Dementia

Related studies from across the Dementia family.

Comprehensive dementia care interventions improve caregiver self-efficacy in those with lower baseline scores
Physical Medicine & Rehab RCT
Comprehensive dementia care interventions improve caregiver self-efficacy in those with lower baseline scores Comprehensive Care Programs May Improve Confidence for Dementia Caregivers
This secondary analysis of a randomized pragmatic clinical trial involved 2037 caregivers of community-dwelling persons living with dementia…
Caregivers of people with dementia can improve their self-efficacy and confidence through comprehensive care programs.
Non-pharmacological interventions for sleep disturbances in mild cognitive impairment and early dementia provide management guidance
Palliative Care Guideline
Non-pharmacological interventions for sleep disturbances in mild cognitive impairment and early dementia provide management guidance Sleep Care Plan for Early Dementia: Best Evidence
This integrative review and guideline identifies 44 evidence items across 11 themes for managing sleep disturbances in patients with mild co…
A new review maps 44 best evidence items for managing sleep problems in mild cognitive impairment and early dementia.
Impact of Domain Specific Physical Activity on Risk of All Cause Dementia
Neurology Meta-analysis
Impact of Domain Specific Physical Activity on Risk of All Cause Dementia High levels of physical activity linked to lower dementia risk
A massive meta-analysis of over 4 million participants reveals that specific types of physical activity significantly influence dementia ris…
Active lifestyles, especially during leisure time, are linked to a lower risk of developing Alzheimer's and other forms of dementia.
Increased Risk of Dementia Diagnosis Among Individuals Diagnosed With Bipolar Disorder
Psychiatry Meta-analysis
Increased Risk of Dementia Diagnosis Among Individuals Diagnosed With Bipolar Disorder Bipolar disorder linked to triple dementia risk
A large-scale meta-analysis identifies a significant correlation between bipolar disorder and an elevated risk of dementia diagnosis.
People with bipolar disorder face a higher risk of dementia, a new analysis finds. The link is strong but the evidence has limits.
Dementia prevalence 24.3% in older adults with psychotic disorders, meta-analysis finds
Psychiatry Meta-analysis
Dementia prevalence 24.3% in older adults with psychotic disorders, meta-analysis finds Dementia found in 1 in 4 older adults with psychotic disorders
This meta-analysis of older adults with psychotic disorders reports a pooled dementia prevalence of 24.3% (95% CI: 20.5%-28.5%), with high h…
A new analysis finds dementia in 24.3% of older adults with psychotic disorders, highlighting the need for better care planning.
Animal-assisted interventions improve depression in dementia, but not other outcomes
Physical Medicine & Rehab Meta-analysis
Animal-assisted interventions improve depression in dementia, but not other outcomes Animal interactions may help ease depression in people with dementia
This overview of systematic reviews and meta-analyses found moderate evidence that animal-assisted interventions (AAIs) improve depression i…
Interacting with animals can significantly improve feelings of depression for people living with dementia, according to a review of recent r…
Prolonged FVEP-P2 latency is associated with Alzheimer's disease and other forms of dementia
Neurology Meta-analysis
Prolonged FVEP-P2 latency is associated with Alzheimer's disease and other forms of dementia Brain Signal Delays Linked to Alzheimer's and Dementia Types
This meta-analysis of 18 comparisons involving 1,778 participants found significantly prolonged FVEP-P2 latency in patients with Alzheimer's…
A large review found that specific brain signal delays are linked to Alzheimer's disease and other forms of cognitive decline.
Person-centered non-pharmacological interventions significantly reduce verbal agitation in patients with dementia
Neurology Meta-analysis
Person-centered non-pharmacological interventions significantly reduce verbal agitation in patients with dementia Personalized care helps reduce agitation in people with dementia
This meta-analysis of randomized controlled trials evaluates the impact of person-centered non-pharmacological interventions on agitation in…
Tailored, person-centered care can significantly lower verbal agitation in people living with dementia compared to standard methods.
SGLT2 inhibitors significantly reduce dementia risk in patients with type 2 diabetes
Diabetes & Endocrinology Meta-analysis
SGLT2 inhibitors significantly reduce dementia risk in patients with type 2 diabetes Diabetes drugs may lower dementia risk, study finds
This network meta-analysis involving 845,433 participants analyzed the impact of SGLT2 inhibitors on dementia outcomes in patients with type…
A large analysis of over 845,000 people with type 2 diabetes found that certain diabetes drugs, especially empagliflozin, were linked to a l…
Gabapentinoid use is associated with modestly higher odds of Alzheimer's disease and related dementias
Neurology Meta-analysis
Gabapentinoid use is associated with modestly higher odds of Alzheimer's disease and related dementias Reviewing the Link Between Gabapentin Use and Risk of Developing Dementia
This meta-analysis of 325,245 individuals found that gabapentinoid use was associated with modestly higher odds of Alzheimer's disease and r…
A large review looked at how gabapentin and pregabalin affect brain health. Some findings suggest a possible link to dementia.
Diabetic retinopathy is associated with a significantly higher risk of all-cause dementia
Diabetes & Endocrinology Meta-analysis
Diabetic retinopathy is associated with a significantly higher risk of all-cause dementia Diabetic retinopathy is linked to a higher risk of dementia
This meta-analysis of observational studies involving 2,887,409 patients found that diabetic retinopathy is associated with an increased ris…
A large analysis shows people with diabetic retinopathy may face an increased risk of developing dementia, highlighting the need for closer …
Elevated neutrophil-to-lymphocyte ratio correlates with greater cerebral small vessel disease burden and white matter hyperintensities
Neurology Meta-analysis
Elevated neutrophil-to-lymphocyte ratio correlates with greater cerebral small vessel disease burden and white matter hyperintensities High Neutrophil Levels Linked to Brain Small Vessel Damage
This systematic review and meta-analysis of 62,961 patients found that elevated neutrophil-to-lymphocyte ratio (NLR) is associated with the …
A large analysis finds that higher neutrophil-to-lymphocyte ratios are linked to more severe damage in the brain's small blood vessels.